Naltrexone for Weight Loss in 2026: Does It Work?

Naltrexone for weight loss works in only one FDA-approved form: paired with bupropion as the branded medication Contrave. It treats a different problem than GLP-1 therapy does. Instead of slowing digestion or blunting appetite hormones, it dials down the reward-driven urge to eat that patients describe as constant "food noise": the looping, intrusive thoughts about food that show up whether or not you're actually hungry.

Why naltrexone matters for adults with constant food noise

Most weight-loss advice assumes the problem is behavioral: portion sizes, snacking at night, not enough willpower at the vending machine. For a specific group of patients that framing is wrong, and it wastes years.

This is the audience the Cardiometabolic Optimization Membership was built to serve differently: labs first, medication second, never the other way around. Adults who describe their eating as "I think about food all day even when I'm full" are asking a fundamentally different question than adults asking how to lose the last ten pounds before a wedding. The guide on GLP-1 therapy for adults dealing with constant food noise covers the GLP-1 side of that question in depth; this guide covers where naltrexone fits, and where it doesn't.

How to evaluate naltrexone for food-noise-driven weight loss

Confirm your food noise is signal-driven, not habit-driven

Before any medication conversation, separate two very different patterns that get lumped together as "cravings."

• Habit-driven eating: triggered by time of day, boredom, stress, or environment, and it responds to changing the environment
• Signal-driven food noise: intrusive, repetitive thoughts about specific foods that persist regardless of recent meals, fullness, or willpower
• Track it for 7-10 days: note whether the thought shows up on a schedule (habit) or randomly, unprompted, even right after eating (signal)
• Ask whether the thoughts feel like planning versus feel like an itch you can't ignore
• If it's the second pattern, medication that targets reward circuitry is worth discussing; if it's the first, environment and structure usually solve it without a prescription

Get baseline labs before assuming it's willpower

Food noise that looks psychological is sometimes metabolic. Insulin resistance, thyroid dysfunction, and hormone imbalance all drive appetite dysregulation that mimics a "discipline problem" on the surface.

• Fasting insulin and HbA1c, not just fasting glucose, to catch early insulin resistance
• A full thyroid panel beyond TSH alone
• Full hormone panel: for men, total and free testosterone; for women, estradiol and progesterone depending on cycle stage
• hs-CRP as a marker of the inflammation that also disrupts appetite signaling

This is where GoodLife Health's clinical protocols diverge from a self-directed trial-and-error approach. The membership's quarterly Biomarker Audit runs these panels every 90 days specifically so a clinician can rule out a metabolic driver before naltrexone, Contrave, or any medication gets prescribed. Skipping this step is the single most common reason patients try a medication and it does nothing: they're treating a symptom whose actual cause is a thyroid number nobody checked.

Understand what naltrexone actually does to appetite signaling

Naltrexone is an opioid receptor antagonist, originally approved for alcohol and opioid dependence. It blocks the reward reinforcement that makes eating certain foods feel compulsively satisfying. On its own, it has a modest and inconsistent effect on weight.

Combined with bupropion, an antidepressant that affects dopamine and norepinephrine, the pairing works on two arms of the same reward pathway at once. That combination, branded as Contrave, is the only naltrexone-containing product the FDA has approved specifically for chronic weight management.

Compare naltrexone-only, Contrave, and GLP-1 therapy for food noise

This is the decision most patients actually need help with, and it's rarely framed honestly. Naltrexone alone is not a weight-loss drug in the FDA's eyes. Contrave is, and it works on reward-driven eating specifically. GLP-1 medications work on a completely different lever: appetite hormones, gastric emptying, and satiety signaling from the gut.

Some patients need one, some need the other, and a smaller group benefits from a clinician managing both over time. GoodLife Health's breakdown of naltrexone-bupropion under medical supervision walks through where this option fits for patients who don't qualify for or don't want a GLP-1 injection.

Start under physician supervision, not a self-directed trial

• Confirm dosing and titration schedule with a licensed clinician, not a forum thread
• Get a full medication and history review first: naltrexone-bupropion carries a boxed warning around suicidal thoughts and behavior, and bupropion lowers seizure threshold
• Disclose any opioid use, since naltrexone blocks opioid receptors and can trigger acute withdrawal in anyone using opioids
• Set a follow-up checkpoint at 12 weeks, the standard window used in the original trials to judge whether the medication is working

Track food noise, not just the scale

Weight is a lagging indicator. Food noise reduction shows up faster and tells you sooner whether the medication is doing its job.

• Rate intrusive food thoughts daily on a simple 1-10 scale for the first 4-6 weeks
• Note whether cravings for specific foods (sugar, fried food, late-night snacking) drop in frequency
• Track whether you can leave food on the plate without it feeling difficult
• Bring this log to your clinician visit; it's more actionable than the number on the scale alone

Watch for interactions and side effects

Nausea, headache, constipation, and insomnia are the most commonly reported side effects of naltrexone-bupropion in published trial data. Most are dose-related and improve with the standard titration schedule rather than jumping straight to a full dose.

Comparing weight-loss medication options for food noise

Contrave wins for patients whose eating is specifically reward-driven and who want an oral, non-injectable option; it is not the stronger choice for patients whose main issue is appetite hormone dysregulation, where GLP-1 therapy consistently outperforms it on average weight loss.

Common mistakes adults with food noise make

• Assuming it's a willpower problem and skipping labs entirely. Thyroid dysfunction, insulin resistance, and low testosterone or estrogen all mimic food noise, and treating the wrong root cause wastes months.
• Self-sourcing naltrexone or research peptides online without a clinician. Adults chasing a DIY fix sometimes end up comparing research-grade peptide suppliers on price per milligram instead of asking whether the substance needs a prescription, a monitored dose, and follow-up labs at all. That question matters more than the price comparison.
• Stopping at four weeks because the scale hasn't moved. Contrave's own trial data used a 12-week checkpoint; judging it earlier misreads the timeline.
• Ignoring the boxed warning conversation. Naltrexone-bupropion is not a casual supplement swap; the mood-related warning is a real clinical consideration a physician needs to review against personal and family history.
• Treating GLP-1 and naltrexone as competing rather than complementary. Some patients' food noise has both a hormonal and a reward-driven component, and the right answer is a clinician-managed plan, not a single drug chosen off a forum recommendation.

FAQ

Is naltrexone FDA-approved for weight loss?

Naltrexone alone is not FDA-approved for weight loss. The FDA-approved product is the combination naltrexone-bupropion, sold under the brand name Contrave, approved in 2014 for chronic weight management.

What's the difference between naltrexone and Contrave?

Naltrexone is one ingredient; Contrave is the branded combination of naltrexone and bupropion. Only the combination has FDA approval for weight loss, because the two drugs work on complementary reward pathways.

Does naltrexone reduce food noise the way GLP-1 medications do?

Naltrexone-bupropion targets reward-driven eating specifically, which overlaps with what patients describe as food noise, but through a different mechanism than GLP-1 drugs like Zepbound or Wegovy, which act on appetite hormones and gastric emptying.

Can you take naltrexone with a GLP-1 medication like Zepbound or Wegovy?

Combining medication classes is a decision for a licensed clinician managing both, based on labs and response, not a self-directed choice. Some patients' food noise has both a reward-driven and hormonal component that benefits from a coordinated plan.

How much weight do people typically lose on naltrexone-bupropion?

Published Contrave trial data shows more modest average weight loss than GLP-1 medications; semaglutide averaged roughly 15% in the STEP-1 trial and tirzepatide reached up to about 22.5% in SURMOUNT-1, for comparison. Individual results vary by patient.

What are the side effects of naltrexone for weight loss?

The most commonly reported side effects of naltrexone-bupropion in trial data are nausea, headache, constipation, and insomnia, most of which improve during the standard titration schedule. It also carries a boxed warning regarding mood and suicidality that requires clinician review.

Who should not take naltrexone or Contrave?

Anyone currently using opioids should not take naltrexone, since it can trigger acute withdrawal. Patients with a seizure history, uncontrolled hypertension, or certain psychiatric histories need a physician's review before starting the bupropion component.

How do you get naltrexone prescribed for weight loss?

A licensed clinician reviews your history, current medications, and baseline labs before prescribing naltrexone-bupropion, then sets a follow-up checkpoint, typically around 12 weeks, to judge whether it's working for your specific pattern of eating.

One last thing

The detail most patients miss: naltrexone-bupropion and GLP-1 therapy aren't competing on the same axis. One quiets the reward system; the other resets the appetite-hormone system. Adults who assume they need to pick a side often do better once a clinician identifies which system is actually driving their food noise, using labs instead of a guess. That's the entire premise behind running a Biomarker Audit every 90 days instead of prescribing off a symptom list in 2026.

Related guides

• Best weight loss medications for patients who can't take GLP-1s
• Why diets fail and how a medical weight loss plan differs

References

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/